首页> 外国专利> Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods

机译:神经衰减氯胺酮和瘤醇类化合物,其衍生物和方法

摘要

The present invention is directed to novel neuro-attentuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.;
机译:本发明涉及根据根据任何一种(下图),(IA)和(IB)的新型神经关注的Norketamine(Nanket)化合物,或表AD中描述的任何化合物,或者在任何一种中本文提供的实施例,其药学上可接受的盐,新药制剂及其新用途方法。本发明还具有新型口腔神经衰减氯胺酮(Naket)和神经衰减的瘤型(NANKET)改性 - 释放药物制剂,以及其新的给药方法,确保治疗有效量的氯胺酮,Norketamine的稳定释放,或其衍生物来自口腔改性的药物制剂,没有神经毒性毒性的氯胺酮浓度在释放期间的缩水酮,无甲胺或衍生物的血浆浓度。

著录项

  • 公开/公告号US10981859B2

    专利类型

  • 公开/公告日2021-04-20

    原文格式PDF

  • 申请/专利权人 AMORSA THERAPEUTICS INC.;

    申请/专利号US201916271767

  • 发明设计人 ALEX NIVOROZHKIN;NELSON LANDRAU;

    申请日2019-02-08

  • 分类号A61K45/06;C07C225/20;C07B59;A61K9/20;A61K31/135;

  • 国家 US

  • 入库时间 2024-06-14 21:26:35

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号